Jason Gerberry

do you see these as agents that maybe you know, appeal more to community providers

can you remind us why you opted not to enrich in the SSP trial for atherosclerosis

does this provide any concerning read-through to some of the ongoing readouts for LITESPARK-022 and the ability to see OS benefit there

how you're thinking about the value add of the GLP-one amylin injectable combination relative to the monotherapy

can you discuss your specialty sales force strategy? And what percent of the market are you -- do you think you'll be able to access

just on the enterprise review and just why not an update today versus giving the update on 1Q '26

in a scenario where, I guess, the ban isn't lifted, do the price penalties, which I think were $100 million, did they recur in that scenario

I know this isn't like a new product issue, but like is generic Symbicort a headwind in 2025, due to competition

why does the Indore facility issues have an impact on revenues outside the United States